{"schema_version":"secwatch.filing_event.v1","accession":"0001127537-24-000045","form_type":"8-K","ticker":"LUNG","cik":"0001127537","company_name":"Pulmonx Corp","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.380140+00:00","generated_at":"2026-06-03T02:05:07.677759+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pulmonx Q1 revenue $18.9M (+30% YoY); net loss narrows to $13.7M","bullets":["Q1 revenue $18.9M, up 30% YoY (29% constant currency); U.S. revenue $12.9M (+38%).","Net loss $13.7M ($0.36 per share) versus $15.9M ($0.42) in Q1 2023; Adjusted EBITDA loss $8M vs $11.2M.","Gross margin 75% (vs 73% YoY); FY 2024 revenue guidance reaffirmed $81M-$84M; operating expenses guidance tightened to $127M-$129M.","Cash and equivalents $120.4M; clinical milestones: first AeriSeal CONVERT II patient and first Japanese Zephyr post-approval patient."],"urls":{"canonical":"https://secwatch.observer/filing/0001127537-24-000045","json":"https://secwatch.observer/filing/0001127537-24-000045.json","markdown":"https://secwatch.observer/filing/0001127537-24-000045.md","text":"https://secwatch.observer/filing/0001127537-24-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1127537/000112753724000045/0001127537-24-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1127537/000112753724000045/lung-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:05:07.677759+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}